Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CDK9 | P50750 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | CASR | P41180 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9306555 | 1.00 | HSD17B10 (1.00) | HSD17B10MTOREPHX2EPHX1TSHR | |
| SCHEMBL6054883 | 0.90 | HSD17B10 (0.81) | HSD17B10MTORSMN1; SMN2CASRCYP2C9 | |
| SCHEMBL16942602 | 0.90 | HSD17B10 (0.81) | HSD17B10MTOREPHX1CASRCYP2C9 | |
| SCHEMBL16942608 | 0.90 | HSD17B10 (0.81) | HSD17B10MTOREPHX1CASRCYP2C9 | |
| SCHEMBL16946640 | 0.90 | HSD17B10 (0.81) | HSD17B10MTORSMN1; SMN2CASRCYP2C9 | |
| SCHEMBL8169526 | 0.90 | HSD17B10 (0.81) | HSD17B10MTORSMN1; SMN2CASRCYP2C9 | |
| SCHEMBL23718858 | 0.89 | HSD17B10 (0.79) | HSD17B10MTOREPHX2TSHRCYP2C9 | |
| SCHEMBL11615932 | 0.89 | HSD17B10 (0.79) | HSD17B10MTOREPHX2TSHRCLK4 | |
| SCHEMBL23199937 | 0.89 | HSD17B10 (0.79) | HSD17B10MTOREPHX2TSHRCYP2C9 | |
| SCHEMBL3461830 | 0.89 | HSD17B10 (0.79) | HSD17B10MTORCASRCYP2C9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946033-A | Preparation method for photo-promoted synthesis of urea compound | 兰州大学 | 2024-04-30 | — | — | CN | claimed |
| JP-6072811-A | — | — | None | — | — | JP | disclosed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| EP-3949000-B1 | LITHIUM BATTERY COMPRISING A UREA-BASED COMPOUND AS ELECTROLYTE ADDITIVE | BAYERISCHE MOTOREN WERKE AG (DE) | 2025-04-30 | — | — | EP | disclosed |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | disclosed |
| US-20240307546-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-117946033-A | Preparation method for photo-promoted synthesis of urea compound | 兰州大学 | 2024-04-30 | — | — | CN | disclosed |
| US-20220173435-A1 | LITHIUM BATTERY AND USE OF A UREA-BASED ELECTROLYTE ADDITIVE AS AN ELECTROLYTE ADDITIVE THEREIN | BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT (DE) | 2022-06-02 | — | — | US | disclosed |
| EP-3949000-A1 | LITHIUM BATTERY AND USE OF A UREA-BASED ADDITIVE AS AN ELECTROLYTE ADDITIVE CONTAINED THEREIN | Bayerische Motoren Werke Aktiengesellschaft (DE) | 2022-02-09 | — | — | EP | disclosed |
| EP-3947352-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA Pharmaceuticals, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026729-A | Lithium battery and use of urea-based additives as electrolyte additives therein | 宝马股份公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2021189013-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | CALCIMEDICA, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| CN-110878035-B | Method for preparing symmetrical urea compound | 中国科学院化学研究所 | 2021-01-05 | — | — | CN | disclosed |
| WO-2020205501-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| CN-110878035-A | Method for preparing symmetrical urea compound | 中国科学院化学研究所 | 2020-03-13 | — | — | CN | disclosed |
| JP-H0672811-A | HERBICIDE FOR PADDY RICE HAVING DECREASED PHYTOTOXICITY | SDS BIOTECH KK | 1994-03-15 | — | — | JP | disclosed |
| JP-H00672811-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | ORAI1, MAVS, CASR | HSD17B10 4101/4885MTOR 226/4885EPHX2 2544/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | HSD17B10 3539/4885MTOR 4235/4885EPHX2 2626/4885 |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | IL1B, MAVS, MMP8 | HSD17B10 3880/4885MTOR 1264/4885EPHX2 2452/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | HSD17B10 4267/4885MTOR 2504/4885EPHX2 3141/4885 |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | HSD17B10 3664/4885MTOR 4021/4885EPHX2 1875/4885 |
| US-20240307546-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | HSD17B10 3664/4885MTOR 4021/4885EPHX2 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.